Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent extension requests

Executive Summary

FDA review periods for three drugs determined. Merck's Prinivil (lisinopril) had a review period of 2,373 days (1,751 during IND and 622 during NDA); Merck is seeking 676 days of patent extension. Sterling's Corotrope (milrinone lactate) review period was 2,205 days (1,287 during IND and 918 during NDA); the company is seeking 730 days of patent extension. Kendall McGaw's Ucephan (sodium benzoate) had a 2,871 day review (2,058 IND; 813 NDA). Kendall is also seeking 730 days of patent extension. The Patent Office makes the final determination of the length of extension.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS013773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel